相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Shirish Gadgeel et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic
Anne-Marie C. Dingemans et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Upheaval in cancer care during the COVID-19 outbreak
Omolola Salako et al.
ECANCERMEDICALSCIENCE (2020)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer
Jia Li Low et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.
Mallika Lala et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dose Rationalization of Pembrolizumab and Nivolumab Using Pharmacokinetic Modeling and Simulation and Cost Analysis
Kayode Ogungbenro et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity
Shin Hye Yoo et al.
ESMO OPEN (2018)
Time dependent pharmacokinetics of pembrolizumab in patients with solid tumor and its correlation with best overall response
Hongshan Li et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2017)
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Daniel A. Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer
Peter B. Bach et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond
Lee Pai-Scherf et al.
ONCOLOGIST (2017)
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer
Daniel A. Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer
Peter B. Bach et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Evaluation of dosing strategy for pembrolizumab for oncology indications
Tomoko Freshwater et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic
S. P. Kang et al.
ANNALS OF ONCOLOGY (2017)
Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
R. Hui et al.
ANNALS OF ONCOLOGY (2017)
Population Pharmacokinetic/Pharmacodynamic Modeling of Tumor Size Dynamics in Pembrolizumab-Treated Advanced Melanoma
M. S. Chatterjee et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Using Model-Based Learn and Confirm to Reveal the Pharmacokinetics-Pharmacodynamics Relationship of Pembrolizumab in the KEYNOTE-001 Trial
J. Elassaiss-Schaap et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer
Thu Oanh Dang et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
A rational approach to dose optimisation of pembrolizumab and nivolumab using cost analysis and pharmacokinetic modelling and simulation
K. Ogungbenro et al.
ANNALS OF ONCOLOGY (2016)
RECIST 1.1-Update and clarification: From the RECIST committee
Lawrence H. Schwartz et al.
EUROPEAN JOURNAL OF CANCER (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development
Ralph E. Parchment et al.
SEMINARS IN ONCOLOGY (2016)
Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer
Charlotte Roach et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2016)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The weight of nations: an estimation of adult human biomass
Sarah Catherine Walpole et al.
BMC PUBLIC HEALTH (2012)
US Outbreak Investigations Highlight the Need for Safe Injection Practices and Basic Infection Control
Joseph F. Perz et al.
Clinics in Liver Disease (2010)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Y Iwai et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
分享论文
